Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELTX Stock Forecast 2026-2027
$14.85
Current Price
$283.43M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELTX Price Targets
+81.8%
To High Target of $27.00
+21.2%
To Median Target of $18.00
+14.5%
To Low Target of $17.00
ELTX Price Momentum
+12.0%
1 Week Change
+36.2%
1 Month Change
+95.4%
1 Year Change
+86.6%
Year-to-Date Change
-7.2%
From 52W High of $16.00
+101.5%
From 52W Low of $7.37
📊 TOP ANALYST CALLS
Did ELTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elicio is one of their latest high-conviction picks.
Latest ELTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ELTX has a bullish consensus with a median price target of $18.00 (ranging from $17.00 to $27.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $14.85, the median forecast implies a 21.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mayank Mamtani at B. Riley Securities, projecting a 81.8% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 14.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELTX Analyst Ratings
3
Buy
0
Hold
0
Sell
ELTX Price Target Range
Low
$17.00
Average
$18.00
High
$27.00
Current: $14.85
Latest ELTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2026 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $27.00 |
| May 28, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $17.00 |
| Apr 15, 2026 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Mar 13, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 10, 2026 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Jul 17, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | Jones Trading | Buy | Initiates | $N/A | |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 1, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 1, 2024 | Oppenheimer | Perform | Reiterates | $N/A | |
| Jan 17, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 26, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Assumes | $12.00 |
Elicio Therapeutics Inc. (ELTX) Competitors
The following stocks are similar to Elicio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ELTX
Elicio Therapeutics
mkt cap
283.43M
Elicio Therapeutics Inc. (ELTX) Financial Data
Elicio Therapeutics Inc. has a market capitalization of $283.43M with a P/E ratio of 5.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -1,076.3%.
Valuation Metrics
Market Cap
$283.43M
Enterprise Value
$265.45M
P/E Ratio
5.8x
PEG Ratio
-0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
2.2x
Debt/Equity
-10.0x
ROE
-1,076.3%
ROA
-92.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elicio Therapeutics Inc. (ELTX) Business Model
About Elicio Therapeutics Inc.
What They Do
Develops targeted immunotherapies for cancer treatment.
Business Model
Elicio Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development and commercialization of innovative immunotherapy products. The company focuses on creating lymph node-targeted therapies, with its lead candidate, ELI-002, currently undergoing Phase II clinical trials aimed at treating pancreatic cancer driven by KRAS mutations.
Additional Information
The proprietary Amphiphile platform enables targeted delivery of immunotherapeutics, potentially leading to improved patient outcomes. Elicio's pipeline also includes additional candidates for other cancer types, indicating a broad approach to tackling significant cancer challenges. The company's focus on enhancing immune responses positions it uniquely in the competitive landscape of cancer immunotherapy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Mr. Robert T. Connelly
Country
United States
IPO Year
2021
Website
elicio.comElicio Therapeutics Inc. (ELTX) Latest News & Analysis
Latest News
Quick Summary
Elicio Therapeutics published a peer-reviewed study on novel AMP-DNA adjuvant candidates, showing potential for robust immune responses in cancer treatment.
Why It Matters
Elicio's publication in a reputable journal validates its AMP-DNA adjuvant research, potentially enhancing investor confidence in its innovative cancer therapies and future market prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
1 month ago
Quick Summary
Elicio Therapeutics raised approximately $13 million through its at-the-market program in Q1 and Q2 2026. The Phase 2 AMPLIFY-7P study results for ELI-002 7P are expected mid-2026.
Why It Matters
The upcoming DFS analysis for ELI-002 7P in pancreatic cancer is pivotal, potentially influencing Elicio's stock performance and investor sentiment based on trial outcomes and funding status.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elicio Therapeutics executives will present at the Bank of America Healthcare Conference on May 14, 2026, at 12:20 PM ET. A live webcast will be available for 90 days post-event.
Why It Matters
Elicio's participation in a major healthcare conference highlights its visibility and potential, attracting investor interest in its cancer immunotherapy pipeline and overall market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elicio Therapeutics (ELTX) is nearing a pivotal trial readout for its KRAS peptide vaccine, with 2026 seen as crucial for KRAS therapies. However, the company faces cash position concerns ahead of key data.
Why It Matters
Elicio Therapeutics' upcoming trial results could drive stock volatility, while its cash concerns raise risks. Successful data may attract investment, affecting share performance significantly.
Source: Seeking Alpha
Market Sentiment:
Neutral
Elicio Therapeutics Reports Inducement Grants
1 month ago
Quick Summary
Elicio Therapeutics granted 21,210 inducement stock options to a new employee on April 15, 2026, under its 2024 Inducement Incentive Award Plan, approved by its Compensation Committee.
Why It Matters
Elicio's grant of stock options signals confidence in attracting talent, which may enhance its R&D capabilities and potentially lead to advancements in its cancer therapies, affecting future valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
2 months ago
Quick Summary
Wall Street analysts have set price targets for Elicio Therapeutics (ELTX) indicating a potential upside of 42.3%, supported by positive earnings estimate revisions.
Why It Matters
A 42.3% potential upside in Elicio Therapeutics' stock, supported by positive earnings revisions, suggests strong growth prospects and may attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ELTX Stock
What is Elicio Therapeutics Inc.'s (ELTX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Elicio Therapeutics Inc. (ELTX) has a median price target of $18.00. The highest price target is $27.00 and the lowest is $17.00.
Is ELTX stock a good investment in 2026?
According to current analyst ratings, ELTX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELTX stock?
Wall Street analysts predict ELTX stock could reach $18.00 in the next 12 months. This represents a 21.2% increase from the current price of $14.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elicio Therapeutics Inc.'s business model?
Elicio Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development and commercialization of innovative immunotherapy products. The company focuses on creating lymph node-targeted therapies, with its lead candidate, ELI-002, currently undergoing Phase II clinical trials aimed at treating pancreatic cancer driven by KRAS mutations.
What is the highest forecasted price for ELTX Elicio Therapeutics Inc.?
The highest price target for ELTX is $27.00 from Mayank Mamtani at B. Riley Securities, which represents a 81.8% increase from the current price of $14.85.
What is the lowest forecasted price for ELTX Elicio Therapeutics Inc.?
The lowest price target for ELTX is $17.00 from Robert Burns at HC Wainwright & Co., which represents a 14.5% increase from the current price of $14.85.
What is the overall ELTX consensus from analysts for Elicio Therapeutics Inc.?
The overall analyst consensus for ELTX is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are ELTX stock price projections?
Stock price projections, including those for Elicio Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 6:46 AM UTC